Direct oral anticoagulants (DOACs) are a more manageable alternative than vitamin K
antagonists (VKAs) to prevent stroke in patients with nonvalvular atrial fibrillation and to …

Background Serotonin reuptake inhibitor (SRI) antidepressants are implicated in increasing
the risk of bleeding among users; however, the comparative increase in bleeding risk with …

Background Polypharmacy may affect outcomes in patients with atrial fibrillation (AF) using
non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) due …

Objective There is a paucity of evidence concerning the risk of bleeding after hospitalisation
for symptomatic peripheral artery disease (PAD) in everyday clinical practice, as randomised …

This study aimed to analyze associations between genetic variants and the occurrence of
clinical outcomes in dabigatran, apixaban, and rivaroxaban users. This was a retrospective …

Importance Dose-reduced regimens of direct oral anticoagulants (DOACs) may be used for
2 main purposes: dose-adjusted treatment intended as full-intensity anticoagulation (eg, for …

Aims The clinical relevance of common pharmacokinetic interactions with non-vitamin K
antagonist oral anticoagulants (NOACs) often remains unclear. Therefore, the impact of P …

Importance Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed
antidepressants associated with a small increased risk of major bleeding. However, the risk …

Purpose Non-vitamin K antagonist oral anticoagulants (NOACs) are widely used in patients
with atrial fibrillation (AF) because of their effectiveness in preventing stroke and their better …

Aims P‐glycoprotein (P‐gp) and CYP3A4‐interacting drugs influence plasma levels of non‐
vitamin K antagonist oral anticoagulants (NOACs). However, the clinical relevance is …